GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TTY Biopharm Co Ltd (ROCO:4105) » Definitions » Capital Expenditure

TTY Biopharm Co (ROCO:4105) Capital Expenditure : NT$-152.08 Mil (TTM As of Mar. 2025)


View and export this data going back to 2001. Start your Free Trial

What is TTY Biopharm Co Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

TTY Biopharm Co's cash flow for capital expenditures for the three months ended in Mar. 2025 was NT$-41 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2025 was NT$-152.08 Mil.

TTY Biopharm Co Capital Expenditure Historical Data

The historical data trend for TTY Biopharm Co's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TTY Biopharm Co Capital Expenditure Chart

TTY Biopharm Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -181.86 -74.15 -135.50 -99.58 -134.29

TTY Biopharm Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.59 -22.00 -30.77 -57.94 -41.37

TTY Biopharm Co Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-152.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TTY Biopharm Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TTY Biopharm Co Ltd (ROCO:4105) » Definitions » Capital Expenditure
Comparable Companies
TPE:1707 TPE:3705 ROCO:4114 TPE:1789 ROCO:6620 TPE:1720 ROCO:6576 ROCO:6785 ROCO:4123 TPE:4119 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
N/A
Address
No. 3-1, Park Street, 3rd Floor, Nangang District, Taipei, TWN, 11503
Website
https://www.tty.com.tw
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in European and Other Countries. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.

TTY Biopharm Co Headlines

No Headlines